Thermo Fisher Scientific Inc. $TMO Shares Bought by Caitong International Asset Management Co. Ltd

Caitong International Asset Management Co. Ltd raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 291.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,531 shares of the medical research company’s stock after purchasing an additional 1,140 shares during the period. Thermo Fisher Scientific accounts for approximately 0.5% of Caitong International Asset Management Co. Ltd’s portfolio, making the stock its 24th largest holding. Caitong International Asset Management Co. Ltd’s holdings in Thermo Fisher Scientific were worth $743,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of TMO. Silvant Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 11.8% in the third quarter. Silvant Capital Management LLC now owns 3,592 shares of the medical research company’s stock valued at $1,742,000 after acquiring an additional 378 shares in the last quarter. Integrated Investment Consultants LLC purchased a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $220,000. Fulcrum Asset Management LLP boosted its stake in shares of Thermo Fisher Scientific by 1.7% during the 3rd quarter. Fulcrum Asset Management LLP now owns 3,217 shares of the medical research company’s stock worth $1,560,000 after purchasing an additional 54 shares during the last quarter. Apexium Financial LP grew its holdings in shares of Thermo Fisher Scientific by 4.6% during the third quarter. Apexium Financial LP now owns 868 shares of the medical research company’s stock worth $421,000 after buying an additional 38 shares in the last quarter. Finally, Palisade Asset Management LLC purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at approximately $46,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TMO has been the subject of several analyst reports. Robert W. Baird set a $653.00 price target on Thermo Fisher Scientific in a report on Friday, January 30th. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a report on Sunday, December 7th. Finally, Wells Fargo & Company set a $683.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $633.68.

Thermo Fisher Scientific Trading Up 0.7%

Shares of TMO opened at $473.21 on Wednesday. The stock’s fifty day simple moving average is $552.08 and its 200 day simple moving average is $548.74. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $175.79 billion, a P/E ratio of 26.67, a price-to-earnings-growth ratio of 2.72 and a beta of 0.96.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm’s revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the firm posted $6.10 earnings per share. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th will be given a $0.47 dividend. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.60%.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This represents a 3.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president owned 20,752 shares in the company, valued at approximately $11,230,982.40. This represents a 1.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.